The Biowreck Industry

After looking at one of Cathy's top holdings, I decided to look at biotech again. Of note: IBB has underperformed some of the better looking setups because the vaccine makers like Moderna and Biontech hammered the fund. Whether that shifts moving forward we shall see. Options-wise, it's about as expensive (or cheap) to go with IBB as some of the ones below.

Options are more expensive now, but large-cap biotech is still reasonably priced.